Literature DB >> 35549908

Unusual neurological presentation of second stage African trypanosomiasis in a young boy: a case report.

Etedal Ahmed A Ibrahim1,2, Mohammed Gasm Elseed M Elmahal3, Khabab Abbasher Hussien Mohamed Ahmed4, Elfatih A Hasabo5, Mohammed Eltahier Abdalla Omer6.   

Abstract

BACKGROUND: In South Sudan, sleeping sickness is a frequent condition caused by human African trypanosomiasis. There are two stages that are well-known. When the CNS is affected, especially with Trypanosoma gambiense infection, the early hemolymphatic stage and the late encephalitic stage have been observed, including mental, motor, and sensory symptoms. In this case, second-stage African trypanosomiasis manifested itself in an atypical neurological manner. CASE
PRESENTATION: A 16-year-old boy from South Sudan referred to Sudan National Centre for Neurological Sciences, Khartoum, Sudan suffering from non-convulsive status epilepticus, mental deterioration and behavioral changes for the last nine months. He was conscious but disorientated. Low hemoglobin concentration, elevated ESR, enlarged spleen and positive card agglutination test for trypanosomiasis was found in this patient. Electro-encephalogram (EEG) found an on-going generalized seizure activity. The patient showed improvement after management with carbamazepine and tonic.
CONCLUSION: Our case highlights that late second stage African trypanosomiasis with neurological complications such as non-convulsive status epilepticus should be suspected in any patient who developed progressive cognitive decline and behavioral changes following long standing history of African Trypanosomiasis and routine Electro-encephalogram EEG is the best tool to diagnose non convulsive status epilepticus.
© 2022. The Author(s).

Entities:  

Keywords:  Human african trypanosomiasis; Second stage; Sudan; Trypanosoma

Mesh:

Year:  2022        PMID: 35549908      PMCID: PMC9097424          DOI: 10.1186/s12887-022-03313-2

Source DB:  PubMed          Journal:  BMC Pediatr        ISSN: 1471-2431            Impact factor:   2.567


  8 in total

1.  Clinical aspects of 2541 patients with second stage human African trypanosomiasis.

Authors:  Johannes Blum; Caecilia Schmid; Christian Burri
Journal:  Acta Trop       Date:  2005-09-12       Impact factor: 3.112

2.  Epidemiology and control of African trypanosomiasis. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1986

Review 3.  Fexinidazole: First Global Approval.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

Review 4.  Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness).

Authors:  Peter Ge Kennedy
Journal:  Lancet Neurol       Date:  2012-12-21       Impact factor: 44.182

Review 5.  The continuing problem of human African trypanosomiasis (sleeping sickness).

Authors:  Peter G E Kennedy
Journal:  Ann Neurol       Date:  2008-08       Impact factor: 10.422

6.  Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis.

Authors:  Jose R Franco; Pere P Simarro; Abdoulaye Diarra; Jose A Ruiz-Postigo; Mireille Samo; Jean G Jannin
Journal:  Res Rep Trop Med       Date:  2012-08-23

7.  Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.

Authors:  Gerardo Priotto; Serena Kasparian; Wilfried Mutombo; Daniel Ngouama; Sara Ghorashian; Ute Arnold; Salah Ghabri; Elisabeth Baudin; Vincent Buard; Serge Kazadi-Kyanza; Médard Ilunga; Willy Mutangala; Gabriele Pohlig; Caecilia Schmid; Unni Karunakara; Els Torreele; Victor Kande
Journal:  Lancet       Date:  2009-06-24       Impact factor: 79.321

Review 8.  Human African trypanosomiasis.

Authors:  Philippe Büscher; Giuliano Cecchi; Vincent Jamonneau; Gerardo Priotto
Journal:  Lancet       Date:  2017-06-30       Impact factor: 79.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.